eFoodSafety.com, Inc. Enters Biotech Arena with Revolutionary Lyme Disease Product; Human Clinical Trials Currently Underway.

SCOTTSDALE, Ariz. -- Patricia Gruden, President/CEO of eFoodSafety.com, Inc. (OTCBB:EFSF), announced today that Knock-Out Technologies, Ltd., a wholly-owned subsidiary of eFoodSafety.com, Inc., has developed a safe, natural, ingestible product that is believed to eradicate Lyme disease.

Bucks County Clinical Research, Inc., (BCCR) (http://bccrinc.com/), an FDA clinical facility, is conducting the testing of the Lyme disease product under the direction of David J. Miller, D.O., FAAP, Executive Director of BCCR, and Richard M. Goldfarb, M.D., FACS, Medical Director of Research & Development of BCCR, a Director of eFoodSafety.com, Inc., and President of MedElite, Inc., a wholly-owned subsidiary of eFoodSafety.com, Inc.

The protocol guidelines for patient enrollment criteria include patients who have known, laboratory documented Lyme disease and have undergone multiple courses of conventional treatment, but have all relapsed.

In 2003, the National Center for Infectious Diseases (NCID) estimated annual costs for treatment of Lyme disease at $60 million a year in the United States alone.

"We have pursued human clinical trials to prove our groundbreaking technology will be effective in eradicating Lyme disease in patients seeking a permanent solution for their chronic symptoms. We also plan on commencing testing in the near future on a broader spectrum of Lyme disease patients, those who have been newly diagnosed and not responsive to current conventional treatment," stated Mrs. Gruden.

Lyme disease is caused by the bacterium Borrelia burgdorferi and is transmitted to humans by the bite of infected blacklegged ticks. Typical symptoms include fever, headache, fatigue, and a characteristic skin rash called erythema migrans. If left untreated, infection can spread to joints, the heart, and the nervous system. Lyme disease is diagnosed based on symptoms, physical findings (e.g., bullseye rash), and the possibility of exposure to infected ticks; laboratory testing is helpful in the later stages of disease. The ticks that transmit Lyme disease can occasionally transmit other tick-borne diseases as well (Division of Vector-Borne Infectious Diseases) (DVBID); National Center for Infectious Diseases (NCID); Centers for Disease Control and Prevention; http://www.cdc.gov).

About eFoodSafety.com, Inc.

eFoodSafety.com, Inc. is dedicated to improving food and health conditions around the world through its innovative technologies. The company's Knock-Out Technologies, Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product, Big 6 Plus - EPA Reg. No. 82723-1 that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza, and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The company's MedElite, Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It is the exclusive U.S. and worldwide distributor of the Talsyn(TM)-CI/bid Scar Cream that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com). The company is also is a distributor for Cinnergen(TM), a non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism (www.cinnergen.com), and Trimmendous(TM), a weight loss formula focusing on the body's 24-hour metabolic processes. The company has recently entered into a joint venture agreement with CK41 Direct, Inc. to launch an anti-acne skin care system, with a branded name and celebrity spokesperson to-be-announced in the near future.

Safe Harbor Forward-Looking Statements

Statements contained in this release that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are made based on information available as of the date hereof, and the company assumes no obligation to update such forward-looking statements. Editors and investors are cautioned that such forward-looking statements invoke risk and uncertainties and the company's actual results may differ from these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the company's products and services, our ability to continue to develop markets, general economic conditions, our ability to secure additional financing for the company and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.